# Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

> **NCT01517373** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 304 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Placebo
- **DRUG:** PF-04937319 10 mg
- **DRUG:** PF-04937319 50 mg
- **DRUG:** PF-04937319 100 mg
- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT01517373
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2017-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01517373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01517373, "Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01517373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*